Postpartum haemorrhage in anaemic women: assessing outcome measures for clinical trials.

ABSTRACT:

Background

Postpartum haemorrhage (PPH) is a leading cause of maternal mortality worldwide. Maternal anaemia greatly increases the risk of PPH, and over a third of all pregnant women are anaemic. Because anaemia reduces the oxygen-carrying capacity of the blood, anaemic women cannot tolerate the same volume of blood loss as healthy women. Yet the same blood loss threshold is used to define PPH in all women. The lack of an established PPH definition in anaemic women means the most appropriate outcome measures for use in clinical trials are open to question. We used data from the WOMAN-2 trial to examine different definitions of PPH in anaemic women and consider their appropriateness as clinical trial outcome measures.

Main body

The WOMAN-2 trial is assessing tranexamic acid (

SUBMITTER: Brenner A 

PROVIDER: S-EPMC8932334 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature